OA
SAGE

Omega Advisors’s Sage Therapeutics SAGE Stock Holding History

Omega Advisors’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-74,800
Closed -$11.7M – 66
2018
Q2 		$11.7M Buy
74,800
+28,100
+60% +$4.41M 0.41% 52
2018
Q1 		$7.52M Buy
+46,700
New +$7.93M 0.28% 52

Other funds holding SAGE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Omega Advisors's SAGE Position: Q3 2018 in Review

Omega Advisors sold out of Sage Therapeutics (SAGE) in Q3 2018, closing a stake of 74,800 shares — an estimated $11.7M sold.

Omega Advisors first reported a position in SAGE in Q1 2018 and held it in 2 quarters. The position peaked at $11.7M in Q2 2018. 275 funds tracked by Wall St. Rank hold SAGE as of Q3 2018.

  • Omega Advisors reported no remaining Sage Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Omega Advisors sold 74,800 Sage Therapeutics shares in Q3 2018, an estimated $11.7M.
  • Omega Advisors first reported a position in Sage Therapeutics in Q1 2018 and held it in 2 quarters.
  • Omega Advisors's Sage Therapeutics position peaked at $11.7M in Q2 2018.
  • 275 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2018.

Based on Omega Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.